Corcept Therapeutics Incorporat (CORT) Stock Price & How to Invest

Corcept Therapeutics is a commercial-stage pharmaceutical company focused on disorders driven by excess cortisol activity. Its foundation is Korlym (mifepristone), a glucocorticoid receptor modulator approved for hypercortisolism (Cushing's syndrome), which generated the bulk of its ~$761 million in 2025 revenue. The company has spent years building physician awareness that hypercortisolism is more common than historically recognized, driving record new-patient starts, and it is expanding beyond a single product: the FDA approved Lifyorli (relacorilant) for platinum-resistant ovarian cancer in March 2026, and Corcept resubmitted a New Drug Application for relacorilant in Cushing's syndrome in June 2026.

The investment picture is unusual for biotech: Corcept is consistently profitable, carries zero debt, and held roughly $515 million in cash and investments as of March 2026. Management raised full-year 2026 revenue guidance to a $950 million to $1.05 billion range. The counterweight is concentration and legal risk. A court ruling cleared a path for Teva's generic version of Korlym, threatening the franchise that still funds nearly everything, so the bull case rests on relacorilant approvals and the oncology pipeline replacing and outgrowing branded Korlym before generic erosion bites.

Revenue concentration is the defining risk: Korlym still drives the overwhelming majority of sales, and a court ruling has cleared a path for Teva's generic mifepristone, which could erode the flagship franchise faster than the new products scale. Relacorilant approval is not guaranteed, as evidenced by an earlier FDA complete response letter before the June 2026 resubmission. Teva has also raised antitrust-style allegations about Corcept's distribution and patent practices, adding litigation overhang. The stock trades at a rich trailing earnings multiple, so any disappointment in guidance, approvals, or generic timing can drive sharp drawdowns, and the oncology launch is early and unproven at scale.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Corcept Therapeutics Incorporat's investor relations page or your broker.

• Revenue (TTM): ~$770M
• FY2025 revenue: ~$761M
• FY2026 revenue guidance: ~$950M to $1.05B
• Market cap: ~$9.4B
• P/E (TTM): ~50x
• Cash & investments / debt: ~$515M / no debt

Corcept is profitable on a full-year basis but posted a Q1 2026 net loss of roughly $32 million as it ramped Lifyorli launch spending (SG&A near $145 million, R&D near $66 million). The trailing P/E near 50x reflects a growth-and-optionality premium rather than a value multiple. The zero-debt balance sheet and half-billion-dollar cash cushion give it flexibility to fund launches and litigation internally.

There are three common ways to get CORT exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so CORT sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where CORT fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

CORT is a profitable single-franchise specialty pharma trying to diversify into oncology and a next-generation Cushing's drug, with generic-Korlym risk as the central overhang.

Whether CORT is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is CORT a buy?, and where the stock could go from here in the CORT stock forecast.

For income investors, whether CORT pays a dividend and how the payout looks is covered in does CORT pay a dividend?